• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Iteos HomeIteos HomeIteos Home

EOS-984

Search

  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
    • Corporate Responsibility
  • Pipeline
    • Our Pipeline
    • Clinical Trials
    • A2A Receptor Antagonist
    • Anti-TIGITmAb FcyR-Engaging
  • Investors
    • Investors Overview
    • News & Events
    • Stock Information
    • Financials
    • Governance
    • Investor Resources
  • Technology
  • Careers
  • Contact

Explore

  • Clinical Trials
  • Inupadenant
  • EOS-448
  • Scientific Publications
  • Our Science
  • Presentations

Search

  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
    • Corporate Responsibility
  • Pipeline
    • Our Pipeline
    • Clinical Trials
    • A2A Receptor Antagonist
    • Anti-TIGITmAb FcyR-Engaging
  • Investors
    • Investors Overview
    • News & Events
    • Stock Information
    • Financials
    • Governance
    • Investor Resources
  • Technology
  • Careers
  • Contact

Explore

  • •Clinical Trials
  • •Inupadenant
  • •EOS-448
  • •Scientific Publications
  • •Our Science
  • •Corporate Presentations
  • Pipeline

    Review our development pipeline, clinical trials, and other innovations.

  • Press

    Explore our latest company news, press releases, and events.

  • Careers

    Discover more about our company culture and explore current openings.

  • ESG

    Review our Environmental, Social and Governance guidelines.

Home / Pipeline / EOS-984

EOS-984

Footer

Cancer immunotherapies
by designTM

iTeos US

321 Arsenal St
Bldg 312, Suite 301
Watertown, MA 02472
United States

iTeos Belgium

Rue des Frères Wright 29
6041 Gosselies
Belgium

  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
    • Corporate Responsibility
  • Pipeline
    • Our Pipeline
    • Clinical Trials
    • A2A Receptor Antagonist
    • Anti-TIGITmAb FcyR-Engaging
  • Investors
    • Investors Overview
    • News & Events
    • Stock Information
    • Financials
    • Governance
    • Investor Resources
  • Technology
  • Careers
  • Contact
Iteos Logo

© 2023 iTeos Therapeutics. iTeos, iTeos logo and Cancer Immunotherapies By Design are trademarks of iTeos Therapeutics Inc.

Privacy Policy   |   Terms of Use

  • Twitter
  • LinkedIn
Manage Cookie Consent
We use necessary cookies on this site, and, if you agree, may set cookies to remember your preferences, analyze website usage and target ads to you, and will share this information with our analytics and advertising partners. To learn more, visit our Cookie Policy. You can change your preferences at any time by clicking on the “Manage Consent” button on our site.
Necessary Always active
We use necessary cookies to help make our website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies. You can set your browser to block these cookies, but without them some parts of the site will not work.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Analytics
We use analytics cookies that allow us to recognise and count the number of visitors and to see how visitors move around the website when they are using it. This helps us to improve the way our website works, for example by making sure users are finding what they need easily. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Advertising
We and our third-party advertising partners use these cookies to collect information about how you use our website and use that information to serve online ads that may be relevant to your interests.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}